Reed Elsevier Plc (ENL, REL.L) Thursday announced that Mr David Brennan has been appointed as a non-executive director of the company.
The company stated that David Brennan will assume office with effect from 1 November 2012, subject to shareholder approval at the respective Annual General Meetings to be held on 24 and 25 April 2012.
Mr Brennan is currently the Chief Executive Officer of AstraZeneca PLC, a global biopharmaceutical company, which develops, manufactures and markets prescription medicines.
Commenting on his appointment, Anthony Habgood, Chairman, said, "I would like to welcome David to Reed Elsevier. He has over 35 years experience in the biopharmaceutical industry and of the development, manufacture and commercialisation of innovative medicines. As a truly international executive with deep knowledge of the world's healthcare markets he will bring highly relevant experience to our board discussions….. '.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org